Scientist in a white lab coat looking into a microscope.

Nucleoside analogs offer an effective treatment for infectious diseases like HBV because of their high barrier to resistance, broad spectrum of activity, and high efficiency.


PROBLEM:

Current attempts to cure HBV infections have been associated with liver toxicity.

SOLUTION:

Riboscience’s ENPP1 inhibitors and nucleoside analogs have the potential to induce curative anti-HBV immune response without causing liver toxicity.


PROBLEM:

Today’s chronic treatments for HBV infections fail to fully suppress viral replication in the liver.

SOLUTION:

Riboscience has nucleosides that have the potential for full viral suppression in the liver.